News Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 03:32:57 2026-05-19 EDT			5-day change	1st Jan Change
1,663.00 ^DKK	-1.63%		-2.89%	-17.96%

05-18	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW

All News

Mentions Relevance

05-18	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
05-13	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
05-13	Genmab A/S : has published its Articles of Association	PU
05-12	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
05-11	Genmab - Major Shareholder Announcement	AQ
05-11	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW
05-09	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis
05-08	Genmab says Orbis Investment Management Limited holds 5.08% of Genmab A/S as of May 8, 2026	RE
05-08	Major Shareholder Announcement	GL
05-08	Goldman Sachs raises Genmab price target to DKK 2,300 (2,200), reiterates Buy - BN	FW
05-07	Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Genmab Q1 Net Profit Falls, Revenue Rises	MT
05-07	Genmab A/S, Q1 2026 Earnings Call, May 07, 2026
05-07	Genmab A/S : Investor Presentation - May 2026	PU
05-07	Genmab reports Q1 operating profit of $180 million	RE
05-07	Genmab A/S : First Quarter 2026 Financial Results Presentation	PU
05-07	Genmab A/S : Interim Report for the First Quarter of 2026	PU
05-07	Genmab operating profit misses expectations	FW
05-07	Genmab Announces Financial Results for the First Quarter of 2026	GL
05-07	Genmab Announces Financial Results for the First Quarter of 2026	AQ
04-22	BNP Paribas Upgrades Genmab to Outperform, Boosts PT	MT
04-22	Goldman Sachs Upgrades Genmab to Buy From Neutral, Adjusts Price Target to $30.50 From $24.50	MT
04-22	Goldman upgrades Genmab to Buy - sees billion-dollar potential in drug pipeline	FW
04-22	BNP Paribas upgrades Genmab to Outperform (Neutral), sets price target at DKK 2,400 - BN	FW